Joyce F. Liu, MD, on Clinical Implications of Using Cediranib Plus Olaparib for Ovarian Cancer

Posted: Tuesday, June 2, 2020

Joyce F. Liu, MD, of Dana-Farber Cancer Institute, discusses phase III data showing that cediranib plus olaparib has similar activity to standard of care in relapsed platinum-sensitive ovarian cancer. Dr. Liu also discusses next steps in the research.